loading page

Efficacy and Safety of finerenone therapy in patients with cardiovascular and chronic kidney diseases in type 2 diabetes mellitus: a systematic review and meta-analysis    
  • +10
  • Mahima Khatri Mahima Khatri,
  • Kamran Mahfooz,
  • Kiran Saleem,
  • Sidra Khalil,
  • Maria Ali,
  • Muhammad Usman,
  • Uroosh Tariq Khanzada,
  • Taha Nadeem,
  • Fatima Tanveer,
  • Rohit Kumar,
  • Vikash Kumar karmani ,
  • Satesh Kumar ,
  • Sumeet kumar
Mahima Khatri Mahima Khatri

Corresponding Author:[email protected]

Author Profile
Kamran Mahfooz
Author Profile
Kiran Saleem
Author Profile
Sidra Khalil
Author Profile
Muhammad Usman
Author Profile
Uroosh Tariq Khanzada
Author Profile
Taha Nadeem
Author Profile
Fatima Tanveer
Author Profile
Rohit Kumar
Author Profile
Vikash Kumar karmani
Author Profile
Satesh Kumar
Author Profile
Sumeet kumar
Author Profile

Abstract

Background and Aims: Finerenone, a nonsteroidal MR antagonist (MRA), enhances renal and cardiovascular outcomes in patients with type 2 diabetes (T2DM). Finerenone’s safety and effectiveness in renal function are debatable. This meta-analysis evaluates the efficacy and safety of treatments for patients with diabetic kidney disease.
Methods: To find relevant RCTs, the databases PubMed, Embase, and Google Scholar were searched. Finerenone’s effects were quantified using estimated pooled mean differences (MDs) and relative risks with 95% confidence intervals (CIs).
Results: This meta-analysis combines seven double-blind trials involving patients with CKD and type 2 diabetes who were randomly assigned to finerenone or placebo. The primary efficacy time-to-event outcomes were cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, heart failure hospitalization, kidney failure, a sustained 57% decrease in estimated glomerular filtration rate from baseline over 4 weeks, or renal death. In this meta-analysis of 39,995 patients, treatment with Finerenone was associated with a lower risk of death due to cardiovascular and renal outcomes than placebo (RR = 0.86 [0.80, 0.93] p=0.0002; I2= 0%) and (RR = 0.56 [0.17, 1.82] p=0.34; I2= 0%), respectively. Finerenone treatment was also associated with a marginally lower risk of serious adverse events (RR = 0.95 [0.92, 0.97] p 0.0001; I2= 0%), but no overall difference in the risk of adverse events was found between the two groups (RR = 1.00 [0.99, 1.01] p=0.56; I2= 0%).
Conclusion: The administration of finerenone decreases the likelihood of end-stage kidney disease, renal failure, cardiovascular death, and hospitalization. Therefore, we propose that patients with T2DM and CKD undergo finerenone therapy.
Keywords: Diabetes, Chronic kidney disease, CKD, Cardiovascular disease, Finerenone, Non-steroidal Mineralocorticoid receptor antagonist, Meta-analysis.